Book Review
No access
Published Online: 27 March 2009

Comparison of Subcutaneous and Intravenous Administration of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor for Peripheral Blood Stem Cell Mobilization

Publication: Journal of Hematotherapy
Volume 4, Issue Number 2


In an effort to determine whether subcutaneous or continuous intravenous infusion administration of rhGM-CSF results in better hematopoietic progenitor mobilization, the findings of two sequential clinical trials were reviewed. Patients who had received prior chemotherapy for leukemia, lymphoma, multiple myeloma, breast cancer, or other solid tumors and were candidates for high-dose therapy received rhGM-CSF, 250 μg/m2/day, either as a continuous intravenous infusion (trial 1) or subcutaneously (trial 2) for stem cell mobilization. At least five apheresis collection procedures were performed to collect a target number of 6.5 x 108 mononuclear cells (MNC)/kg. For the 37 patients in trial 1, the collections contained a median of 7.99 x 108 MNC/L (range 6.42-21.36) and a median of 5.27 x 104 CFU-GM/kg (range 0.28-19.35). In trial 1, 25 patients were autografted with their cells and recovered 0.5 x 109 granulocytes/L at a medin of 12 days (range 6-16). For the 33 patients in trial 2, the autograft product contained a median of 7.63 x 108 MNC/kg (range 6.51-22.66) and 6.31 x 104 CFU-GM/kg (range 0.06-60.4). In trial 2, 25 patients were autografted. The median time to reach 0.5 x 109 granulocytes/L was 11 days (range 9-26). All patients received rhGM-CSF after peripheral stem cell transplant. No significant differences in the collected products or the time to hematopoietic recovery was found between the two trials (p > 0.05). The mobilization effects of subcutaneous rhGM-CSF in these pretreated patients were similar to those of intravenous rhGM-CSF.

Get full access to this article

View all available purchase options and get full access to this article.

Information & Authors


Published In

cover image Journal of Hematotherapy
Journal of Hematotherapy
Volume 4Issue Number 2April 1995
Pages: 81 - 84
PubMed: 7543352


Published online: 27 March 2009
Published in print: April 1995


Request permissions for this article.




Metrics & Citations



Export citation

Select the format you want to export the citations of this publication.

View Options

Get Access

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.

Society Access

If you are a member of a society that has access to this content please log in via your society website and then return to this publication.

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

View options


View PDF/ePub







Copy the content Link

Share on social media

Back to Top